Patent number: 12123059
Abstract: The present invention refers to an in vitro method for predicting cardiotoxicity risk in a cancer patient receiving, or susceptible to receive, anthracyclines chemotherapy based on the determination of the expression levels of a combination of 10 circulating miRNAs consisting of miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA-192-5p, miRNA 215-5p, miRNA 486-3p/486-5p and miRNA-4732-3p, in a biological sample isolated from the patient. The present invention also refers to said set of 10 circulating miRNAs for its use as biomarker of prediction of cardiotoxicity risk in cancer patients receiving, or susceptible to receive, anthracyclines chemotherapy. Finally, a method for the prevention of cardiotoxicity, in patients receiving or susceptible to receive anthracyclines chemotherapy, that comprises modulating the expression levels of the set of said 10 circulating miRNAS is contemplated.
Type:
Grant
Filed:
December 16, 2019
Date of Patent:
October 22, 2024
Assignees:
Fundación Para La Investigación Del Hospital Universitario La Fe De La Comunidad Valenciana, Maastricht University
Inventors:
David Hervàs Marin, Ana Santaballa Beltràn, Carmen Salvador Coloma, Rubèn Carrero Garcìa, Rafael Sanchez Sanchez, Akaitz Dorronsoro Gonzàlez, Imelda Ontoria Oviedo, Sandra Tejedor Gascòn, Estaban Peiró Molina, Amparo Hernándiz Martinez, Hernán González-King, María Ciria Calduch, Delia Castellano Izquierdo, Joaquín Panadero Romero, Jose Anastasio Montero Argudo, Pilar Sepúlveda Sanchis, Nahuel A. García, Florian Caiment, Jos Kleinjans, Stephane Heymans, Jort Merken
Publication number: 20220081725
Abstract: The present invention refers to an in vitro method for predicting cardiotoxicity risk in a cancer patient receiving, or susceptible to receive, anthracyclines chemotherapy based on the determination of the expression levels of a combination of 10 circulating miRNAs consisting of miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA-192-5p, miRNA 215-5p, miRNA 486-3p/486-5p and miRNA-4732-3p, in a biological sample isolated from the patient. The present invention also refers to said set of 10 circulating miRNAs for its use as biomarker of prediction of cardiotoxicity risk in cancer patients receiving, or susceptible to receive, anthracyclines chemotherapy. Finally, a method for the prevention of cardiotoxicity, in patients receiving or susceptible to receive anthracyclines chemotherapy, that comprises modulating the expression levels of the set of said 10 circulating miRNAS is contemplated.
Type:
Application
Filed:
December 16, 2019
Publication date:
March 17, 2022
Applicants:
Fundación Para La Investigación Del Hospital Universitario La Fe De La Comunidad Valenciana, Maastricht University
Inventors:
David Hervàs Marìn, Ana Santaballa Beltràn, Carmen Salvador Coloma, Rubèn Carrero Garcìa, Rafael Sanchez Sanchez, Akaitz Dorronsoro Gonzàlez, Imelda Ontoria Oviedo, Sandra Tejedor Gascòn, Estaban Peiró Molina, Amparo Hernàndiz Martinez, Hernán González-King, María Ciria Calduch, Delia Castellano Izquierdo, Joaquín Panadero Romero, Jose Anastasio Montero Argudo, Pilar Sepúlveda Sanchis, Nahuel A. García, Florian Caiment, Jos Kleinjans, Stephane Heymans, Jort Merken
